Core Viewpoint - The company, Aidi Pharmaceutical (688488.SH), has announced the initiation of a Phase III clinical trial for its self-developed HIV drug, ACC017 tablets, which aims to evaluate its efficacy and safety in treatment-naive adults with HIV-1 [1] Group 1: Drug Development - ACC017 tablets are a novel chemical structure classified as a first-class new drug, specifically an integrase strand transfer inhibitor (INSTI) targeting HIV [1] - The Phase III trial is designed as a multicenter, randomized, double-blind, and double-dummy study, with the first subject successfully enrolled on November 7, 2025 [1] Group 2: Clinical Trial Details - The trial will compare ACC017 tablets against a control of multi-raltegravir sodium tablets to assess effectiveness and safety [1] - The primary focus of the clinical trial is to evaluate the drug's ability to block the integration of the HIV genome into the host's DNA [1]

Core Viewpoint - The company, Aidi Pharmaceutical (688488.SH), has announced the initiation of a Phase III clinical trial for its self-developed anti-HIV drug, ACC017 tablets, which aims to evaluate its efficacy and safety in treatment-naive adults with HIV-1 [1] Group 1: Drug Development - ACC017 tablets are a novel chemical structure classified as a first-class new drug, specifically an integrase strand transfer inhibitor (INSTI) targeting HIV [1] - The drug works by inhibiting the activity of the HIV integrase, effectively blocking the integration of the HIV genome into the host's DNA [1] - The first subject for the Phase III clinical trial was successfully enrolled on November 7, 2025 [1] Group 2: Clinical Trial Details - The Phase III trial is designed as a multicenter, randomized, double-blind, and double-dummy study comparing ACC017 with a control of multi-raltegravir sodium tablets [1] - The trial focuses on assessing the drug's effectiveness and safety in a specific patient population, namely treatment-naive adults infected with HIV-1 [1]